Currently, there are 219.02M common shares owned by the public and among those 216.45M shares have been available to trade.
The company’s stock has a 5-day price change of 32.75% and -2.65% over the past three months. MVIS shares are trading -58.65% year to date (YTD), with the 12-month market performance down to -56.69% lower. It has a 12-month low price of $0.80 and touched a high of $2.98 over the same period. MVIS has an average intraday trading volume of 2.94 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 22.74%, 11.63%, and -6.95% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Microvision Inc (NASDAQ: MVIS) shares accounts for 27.60% of the company’s 219.02M shares outstanding.
It has a market capitalization of $250.37M and a beta (3y monthly) value of 2.95. The earnings-per-share (ttm) stands at -$0.42. Price movements for the stock have been influenced by the stock’s volatility, which stands at 17.21% over the week and 9.08% over the month.
Earnings per share for the fiscal year are expected to increase by 13.33%, and 30.77% over the next financial year.
Looking at the support for the MVIS, a number of firms have released research notes about the stock. Cantor Fitzgerald stated their Neutral rating for the stock in a research note on March 07, 2022, with the firm’s price target at $5. Ladenburg Thalmann coverage for the Microvision Inc (MVIS) stock in a research note released on January 26, 2017 offered a Buy rating with a price target of $4.50. Rodman & Renshaw was of a view on December 17, 2015 that the stock is Buy, while Northland Capital gave the stock Outperform rating on November 13, 2013, issuing a price target of $4- $3.50. Northland Capital on their part issued Outperform rating on March 07, 2013.
